The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells

Although melanoma is the most aggressive skin cancer, recent advances in BRAF and/or MEK inhibitors against BRAF-mutated melanoma have improved survival rates. Despite these advances, a treatment strategy targeting NRAS-mutated melanoma has not yet been elucidated. We discovered CH5126766/RO5126766...

Descripción completa

Detalles Bibliográficos
Autores principales: Wada, Makoto, Horinaka, Mano, Yamazaki, Toshikazu, Katoh, Norito, Sakai, Toshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4244135/
https://www.ncbi.nlm.nih.gov/pubmed/25422890
http://dx.doi.org/10.1371/journal.pone.0113217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4244135/
https://www.ncbi.nlm.nih.gov/pubmed/25422890
http://dx.doi.org/10.1371/journal.pone.0113217

Ejemplares similares